Screening for Trials

---

---

Objectives of the ADNeT Screening for Trials Initiative

This initiative seeks to:

• accelerate development of effective therapies to prevent or treat dementia, and
• give more Australians access to the latest potential therapies through participation in trials

We are doing this by collaborating closely with international clinical trials to encourage large trials to be brought to Australia.

This initiative will also help Australian researchers find participants to test their therapeutic discoveries and for longitudinal observational research to learn more about the development of Alzheimer’s disease and other dementias.

ADNeT Screening Sites

ADNeT has established sites that will screen volunteers (including cognitive impaired people) for referral to available clinical trials. We currently have screening sites operating in Melbourne, Adelaide, Sydney, Newscastle, Brisbane, and Perth.

What Do We Screen For?

Slow build-up of two toxic proteins called amyloid and tau are believed to be the cause of Alzheimer’s disease. Previous studies have shown amyloid in all participants with Alzheimer’s disease, but have also observed that amyloid begins to deposit in the brain 15 to 20 years before other symptoms develop. It is also currently believed that amyloid may speed up the formation of the other toxic protein, called tau.

The earlier that drugs designed to slow the build-up of amyloid or to clear it from the brain are given, the greater the chance of preventing this major cause of dementia.

We are developing the best brain scans and blood tests to identify people with brain amyloid so they can participate in early treatment trials aimed to slow the disease and prevent dementia.

Can I Participate In A Trial?

If you would like to participate in a trial, or learn more about participating in a trial, please visit our Research Volunteer Portal

---